logo
Above Food Ingredients Inc. and Palm Global Technologies Advance Strategic Merger with Definitive Agreements Expected to be Signed Imminently

Above Food Ingredients Inc. and Palm Global Technologies Advance Strategic Merger with Definitive Agreements Expected to be Signed Imminently

Regina, Saskatchewan--(Newsfile Corp. - April 30, 2025) - Above Food Ingredients Inc. (NASDAQ: ABVE) ('Above Food') today announced that it has reached agreement on essential terms and conditions for its proposed merger with Palm Global Technologies Ltd. ('Palm Global'), advancing the transformative acquisition first announced on February 6, 2025.
The executive management team of Above Food has completed its comprehensive review of the proposed merger terms and structure, expressing strong support for this transformative combination. The Company's Board of Directors has received the management team's endorsement and is advancing the necessary corporate and regulatory approvals to facilitate the completion of definitive documentation.
The Above Food executive management team travelled to the Emirates this week to conclude final diligence. Additionally, our leadership team attended a number of groundbreaking milestone events that further demonstrated the success that Palm Global is achieving on its global initiatives.
'This milestone solidifies the strong alignment between our organizations on both the vision and structure of this revolutionary merger,' commented Lionel Kambeitz, Founder and CEO of Above Food. 'Our management team strongly supports this combination with Palm Global, which we believe will create substantial value for our shareholders while accelerating our mission of building a more sustainable and inclusive global food system. Palm Global's revolutionary FinTech platform, built on proprietary AI, blockchain, and decentralized finance technologies, and impressive roster of global partnerships, creates an unprecedented go-to-market platform to transform global agriculture. The events we attended in person and the associated announcements expected over the coming days from Palm Global further solidifies our belief that this transaction will significantly enhance shareholder value. We will ensure our shareholders are updated on a timely basis on the exciting progress as they are announced by ourselves or Palm Global.'
About Above Food Ingredients Inc.
Above Food Ingredients Inc. (NASDAQ: ABVE) is an ingredient company that delivers products made with real, nutritious, flavorful ingredients produced with transparency. The Company's vision is to create a healthier world – one seed, one field, and one bite at a time. With a robust chain of custody of plant proteins, enabled by scaled operations and infrastructure in primary agriculture and processing, and proprietary seed development capabilities that leverage the power of artificial intelligence-driven genomics and agronomy, the Company delivers nutritious foods to businesses and consumers with traceability and sustainability.
About Palm Global
Palm Global is a next-generation innovator in financial inclusion, agri-tech, and sustainability, operating out of San Francisco, Dubai, Hong Kong, and Singapore. Utilizing AI, blockchain, and decentralized finance (DeFi) technologies. Palm Global delivers scalable solutions that drive economic empowerment and financial access for millions of farmers across Africa, Southeast Asia, and the Americas. By facilitating access to credit, insurance, and advanced agricultural technologies, through its platforms and super-apps, Palm Global supports sustainable growth and food security at scale. Through strategic partnerships with governments, global institutions, and NGOs, Palm Global is accelerating the adoption of digital solutions that transform global agriculture and strengthen financial resilience in underserved markets. The Palm Global website is available at www.palmglobal.ai
Cautionary Statement Regarding Forward-Looking Statements
This press release may contain 'forward-looking information' within the meaning of the United States federal securities laws and applicable Canadian securities laws. These forward-looking statements generally are identified by the words 'believe,' 'project,' 'expect,' 'anticipate,' 'estimate,' 'intend,' 'strategy,' future,' 'opportunity,' 'plan,' 'may,' 'should,' 'will,' 'could,' 'will be,' will continue,' and similar expressions and include, without limitation, statements about the ability of or expectations regarding the future performance of our business and operations.
Forward-looking statements are based on the current expectations of the Company's management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on, by any investor as a guarantee, an assurance, a prediction or a definitive statement of fact or probability. You should carefully consider all of the risks and uncertainties described in the documents filed by the Company with the United States Securities and Exchange Commission, which is available on EDGAR at www.sec.gov/edgar.shtml. There may be additional risks that the Company presently does not know or that the Company currently believes are immaterial that could also cause actual results to differ from those contained in forward-looking statements. In addition, forward-looking statements provide the Company's expectations, plans or forecasts of future events and views as of the date of this communication. The Company anticipates that subsequent events and developments will cause the Company's assessments to change. However, while the Company may elect to update these forward-looking statements in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's assessments as of any date subsequent to the date of this communication. Nothing herein should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results in such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements in this communication, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein.
Additional Information and Where to Find It:
INVESTORS AND SECURITY HOLDERS OF ABOVE FOOD ARE URGED TO READ THE DOCUMENTS FILED WITH THE SEC, CAREFULLY AND IN THEIR ENTIRETY BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT ABOVE FOOD. Investors and security holders will be able to obtain free copies of the documents filed with the SEC by Above Food through the website maintained by the SEC at http://www.sec.gov. Copies of the documents filed with the SEC by Above Food are also be available free of charge on Above Food's website at https://abovefood.com or by contacting Above Food's Investor Relations Department at 2305 Victoria Ave #001, Regina, Saskatchewan, Canada, S4P 0S7.
Contacts
Media:
[email protected]
Investors:
[email protected]
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/250304

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Insurance tech firm Slide targets over $2 billion valuation in Nasdaq IPO
Insurance tech firm Slide targets over $2 billion valuation in Nasdaq IPO

Yahoo

timean hour ago

  • Yahoo

Insurance tech firm Slide targets over $2 billion valuation in Nasdaq IPO

-- Insurance technology company Slide is pursuing a valuation of up to $2.12 billion in its upcoming initial public offering (IPO) on the Nasdaq exchange. The company disclosed the target in a filing on Monday. In collaboration with some of its existing stakeholders, Slide is aiming to raise up to $340 million from the IPO. This move is in line with a recent trend of successful stock market debuts by insurance firms. Barclays and Morgan Stanley have been named as the lead underwriters for the listing. The shares of the company are anticipated to begin trading on the Nasdaq exchange under the ticker symbol "SLDE". Related articles Insurance tech firm Slide targets over $2 billion valuation in Nasdaq IPO Morgan Stanley downgrades Lululemon on weak US growth outlook Tesla shares slip after double downgrade amid Trump feud fallout Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Sitio Royalties downgraded after Viper Energy agrees to acquire co for $19.41/shr
Sitio Royalties downgraded after Viper Energy agrees to acquire co for $19.41/shr

Yahoo

timean hour ago

  • Yahoo

Sitio Royalties downgraded after Viper Energy agrees to acquire co for $19.41/shr

-- Texas Capital has downgraded Sitio Royalties Corp (NYSE:STR) to Hold from Buy after the company agreed to be acquired by Viper Energy (NASDAQ:VNOM) in an all-stock transaction valued at $19.41 per share. The downgrade comes as analysts no longer see material upside following the announced deal, which values Sitio at about $4.1 billion. Texas Capital also cut its price target on Sitio to $20 from $29, in line with the proposed merger terms. 'We are positive on the transaction,' analysts wrote, citing strategic fit, increased scale, low leverage, and an attractive base dividend breakeven below $20 per barrel WTI. 'The combination creates a must-own Minerals company.' Texas Capital does not expect any competing bids given the lack of well-capitalized public rivals in the space. Viper Energy said the deal will make it the largest public mineral and royalty company in the U.S., with positions in the Permian and other key basins. The transaction is expected to close in the second half of 2025, subject to shareholder and regulatory approvals. Related articles Sitio Royalties downgraded after Viper Energy agrees to acquire co for $19.41/shr Tesla shares gain as Trump wishes Musk 'well' GFL weighs sale in infrastructure arm valued at C$5 billion - Bloomberg Sign in to access your portfolio

Anteris Appoints David Roberts and Gregory Moss to its Board of Directors
Anteris Appoints David Roberts and Gregory Moss to its Board of Directors

Yahoo

timean hour ago

  • Yahoo

Anteris Appoints David Roberts and Gregory Moss to its Board of Directors

New Directors Bring Extensive NASDAQ Expertise Across Legal, Operational and Corporate Leadership Capacities MINNEAPOLIS and BRISBANE, Australia, June 09, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR, ASX: AVR) a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today announced the appointments of Mr. David Roberts and Mr. Gregory Moss to its Board of Directors. The Company also announced the resignation of Dr. Wenyi Gu from the Board upon completion of his term as an Australia-based non-executive director. 'On behalf of the management team and Board, I am delighted to welcome David and Gregory to the Company' commented John Seaberg, Chairman of Anteris. 'On the heels of our Q4 2024 listing onto NASDAQ, and as we ramp-up activities to launch the DurAVR® THV global, pivotal clinical trial (the "PARADIGM Trial"), we are excited to enhance the leadership team with two highly accomplished, U.S. based, healthcare executives as the company transitions to its next phase of growth. I also wish to extend gratitude to Dr. Gu for his commitment and contributions to the company over the course of his tenure as a member of the Board and wish him well on his future endeavors.' Mr. David Roberts is currently President of LeMaitre Vascular, Inc. (NASDAQ: LMAT), a position he has held since 2007. He joined LeMaitre in 1997 as Vice President of Business Development and was promoted to Chief Financial Officer in 2000. Prior to LeMaitre, Mr. Roberts served as Vice President of Development for BUCA, Inc. from 1994 to 1997, and prior to that as Associate of HarbourVest Partners from 1992 to 1994. Mr. Roberts received a Bachelor of Arts in Business Economics and History from Brown University and a Master of Business Administration from the Stanford University Graduate School of Business. Mr. Roberts serves as a director of LeMaitre Vascular, Inc., Lexington Medical, Inc. and Parasole Restaurant Holdings, Inc. Mr. Gregory Moss serves as Chief Business and Legal Officer, as well as Corporate Secretary and Chief Compliance Officer of Evommune, Inc. Prior to Evommune, Mr. Moss served as Executive Vice President, General Counsel, and Corporate Secretary, Chief Compliance Officer at Kadmon, a Sanofi Company, where he led legal, compliance, and business development operations, culminating in Kadmon's $1.9 billion acquisition in 2021. Prior to joining Kadmon in 2012, Mr. Moss served as a solicitor in the corporate risk department of a large Australian law firm and as an associate at a boutique law firm and hedge fund in New York, where he focused on complex litigation and event-driven outcomes. Mr. Moss currently serves on the board of Vitls, Inc. Mr. Moss earned a BA and an LLB from Macquarie University, Australia, and is a member of the Bar Associations of New York, USA, and New South Wales, Australia, with admissions before the Supreme Court of the United States of America; Southern District of New York; Supreme Court of New South Wales, Australia; and High Court of Australia. Mr. Roberts and Mr. Moss will help guide Anteris through its next phase of growth, with the upcoming global pivotal PARADIGM study in 3Q2025 towards the ultimate U.S. and EMA licensure of the DurAVR® THV for patients with aortic stenosis. About Anteris Anteris Technologies Global Corp. (NASDAQ: AVR, ASX: AVR) is a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function. Founded in Australia, with a significant presence in Minneapolis, USA, Anteris is a science-driven company with an experienced team of multidisciplinary professionals delivering restorative solutions to structural heart disease patients. Anteris' lead product, the DurAVR® Transcatheter Heart Valve (THV), was designed in partnership with the world's leading interventional cardiologists and cardiac surgeons to treat aortic stenosis – a potentially life-threatening condition resulting from the narrowing of the aortic valve. The balloon-expandable DurAVR® THV is the first biomimetic valve, which is shaped to mimic the performance of a healthy human aortic valve and aims to replicate normal aortic blood flow. DurAVR® THV is made using a single piece of molded ADAPT® tissue, Anteris' patented anti-calcification tissue technology. ADAPT® tissue, which is FDA-cleared, has been used clinically for over 10 years and distributed for use in over 55,000 patients worldwide. The DurAVR® THV System is comprised of the DurAVR® valve, the ADAPT® tissue, and the balloon-expandable ComASUR® Delivery System. For more information: Investor Relations investor@ OrmsbyAnteris Technologies Global Corp.+61 1300 550 310 | +61 7 3152 3200 Investor Relations (US)mchatterjee@ Chatterjee, Life Science Group+1 917 330 4269WebsiteXFacebookLinkedIn in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store